Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The CDC’s Advisory Committee on Immunization Practices voted April 16 to expand use of respiratory syncytial virus vaccines among high-risk adults. The updated recommendation calls for a single ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Respiratory virus data included in the interactive data application is up-to-date as of April 5, 2025. Among its new features, the dashboard now includes RSV Severe Outcomes data.

Autoimmune disorders develop when your immune system mistakenly attacks your own healthy cells and tissues. Conditions like rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes ...

2 University of Manitoba, Department of Pediatrics, Section of Allergy and Clinical Immunology, Winnipeg, MB 3 University of British Columbia, Department of Pediatrics, Division of Allergy and ...

Immunization is the best way to protect against respiratory syncytial virus (RSV) infections and their complications. It involves administering a preventive treatment or vaccine to help the body ...

Coronavirus and respiratory syncytial virus (RSV) are two kinds ... People over 65 Those with a weakened immune system Those with heart or lung diseases RSV doesn't usually come with long-term ...

Craig Venter Institute (JCVI), the Friedrich-Loeffler-Institut (FLI), and the International Livestock Research Institute (ILRI) have developed a reverse genetics system for African swine fever ...